Nuvation Bio Inc (NUVB) - News Archive

Nuvation Bio Inc. (NYSE: NUVB), a leading global oncology company, is on the forefront of the fight against cancer, focusing its efforts on developing innovative therapies that address the complexities of various malign...

Nuvation Bio Inc. (NYSE: NUVB) stands at a crucial juncture in oncology, presenting both promising clinical advancements with its investigational drug, IBTROZI (taletrectinib), and a complex financial profile that influ...

Nuvation Bio s recent initiatives surrounding the investigational drug taletrectinib illustrate a commitment to addressing significant unmet medical needs in oncology, particularly for patients with advanced ROS1-positi...

Nuvation Bio: Navigating Financial Challenges While Pursuing Oncology Breakthroughs Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage global biopharmaceutical company, recently presented its financial results for th...

Unveiling Taletrectinib s Potential: Nuvation Bio s Success in Advanced ROS1-Positive NSCLC Treatment Positive Data from Phase 2 TRUST-I and TRUST-II StudiesNuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical com...

Nuvation Bio s Advancements in Oncology: Taletrectinib Data Paves the Way for New Drug Application, Financial Outlook Promises GrowthNuvation Bio Inc. (NYSE: NUVB), a pioneering biopharmaceutical company dedicated to ad...

Nuvation Bio: Pioneering Pathways in Oncology with Promising Second Quarter Results In the ever-evolving landscape of oncology therapeutics, Nuvation Bio Inc. (NYSE: NUVB) emerges as a notable player, demonstrating sign...

In an effort to strengthen its commercial capabilities and drive growth amid financial challenges, Nuvation Bio Inc (NYSE: NUVB), a biopharmaceutical company specializing in addressing unmet needs in oncology, has appoi...

Breaking News - NEW YORK: Nuvation Bio Inc. (NYSE: NUVB), a pioneer in developing innovative therapeutic candidates to address critical unmet needs in oncology, has announced its agreement to acquire AnHeart Therapeutic...

Nuvation Bio Inc., a biopharmaceutical company specializing in the development of novel therapeutic candidates for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1/2 study of N...

The biopharmaceutical company, Nuvation Bio Inc., dedicated to addressing critical unmet needs in oncology, has recently reported its financial results for the fourth quarter and full year of 2023, along with a business...

Nuvation Bio Boosts Board of Directors with Addition of Dr. Robert MashalNuvation Bio Inc., a leading biopharmaceutical company focused on addressing significant unmet needs in oncology with innovative therapeutic candi...

Nuvation Bio Inc., a prominent biopharmaceutical company dedicated to addressing significant unmet needs in oncology, has made a significant stride in cancer treatment. The company recently announced that the U.S. Food...

Nuvation Bio Inc., an innovative biopharmaceutical company, recently revealed its financial results for the third quarter of 2023 along with a comprehensive business update. With a strong focus on addressing critical un...